Squarepoint Ops LLC bought a new position in shares of SCYNEXIS, Inc. (NASDAQ:SCYX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 43,859 shares of the company’s stock, valued at approximately $53,000. Squarepoint Ops LLC owned approximately 0.12% of SCYNEXIS as of its most recent filing with the Securities & Exchange Commission. Several other institutional investors and hedge funds have also bought and sold shares of SCYX. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in SCYNEXIS by 22.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 195,393 shares of the company’s stock worth $236,000 after buying an additional 35,233 shares during the last quarter. Millennium Management LLC acquired a new stake in SCYNEXIS during the fourth quarter worth approximately $31,000. Jane Street Group LLC acquired a new stake in SCYNEXIS during the fourth quarter worth approximately $32,000. Northern Trust Corp grew its position in SCYNEXIS by 51.9% during the fourth quarter. Northern Trust Corp now owns 153,518 shares of the company’s stock worth $186,000 after buying an additional 52,466 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new stake in SCYNEXIS during the fourth quarter worth approximately $25,000. Institutional investors own 54.37% of the company’s stock. Analysts Set New Price Targets Separately, Wall Street Zen started coverage on SCYNEXIS in a research report on Friday, May 16th. They set a “sell” rating on the stock. View Our Latest Analysis on SCYX SCYNEXIS Stock Performance Shares of SCYX stock opened at $0.88 on Wednesday. The stock’s fifty day moving average price is $0.90 and its two-hundred day moving average price is $1.03. The company has a market cap of $34.42 million, a PE ratio of -1.19 and a beta of 1.65. SCYNEXIS, Inc. has a fifty-two week low of $0.72 and a fifty-two week high of $2.29. SCYNEXIS (NASDAQ:SCYX – Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%. The firm had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.14 million. About SCYNEXIS (Free Report) SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
